Effects of Darbepoetin Alfa and Ferric Derisomaltose Plus Darbepoetin Alfa in Functional Iron-Deficiency Anemia
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26052203 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sung-Hwa Sohn und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hallym Translational Research Institute, College of Medicine, Hallym University, Anyang-si 14068, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Darbepoetin alfa, Anemia, Iron-Deficiency, Maltose, Ferric Compounds. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Korea Health Technology R&D Project, the Patient-Centered Clinical Research Coordinating Center, Hallym University Research Fund.
Abstract (Originalsprache)
Functional iron-deficiency anemia (FIDA) is a side effect of many cancer treatments, occurring when chemotherapy drugs damage bone marrow cells, which are responsible for producing red blood cells, due to the myelosuppressive effects of chemotherapy, or to the cancer itself. This study was performed to compare the effects of darbepoetin alfa alone, or in combination with ferric derisomaltose in cancer patients with FIDA, and to elucidate the mechanism underlying the effects in F36E cells. F36E cells treated with darbepoetin alfa showed increased cell viability. AML and GC cells treated with darbepoetin alfa, ferric derisomaltose, or ferric derisomaltose plus darbepoetin alfa showed no induction of apoptosis. The effects of these drugs on the anticancer efficacy of PTX chemotherapy were examined by analyzing cell viability and induction of apoptosis. Darbepoetin alfa, ferric derisomaltose, and ferric derisomaltose plus darbepoetin alfa showed no significant inhibitory effects on the apoptosis-inducing activity of PTX in GC cell lines. Patients with chemotherapy-induced FIDA in Group I receiving ferric derisomaltose plus darbepoetin alfa showed higher hemoglobin levels, transferrin saturation, and ferritin levels compared to those in Group II, treated with darbepoetin alfa alone. In cancer patients with FIDA, the prognosis of anemia treatment was better in the ferric derisomaltose plus darbepoetin alfa combination group than in the group receiving darbepoetin alfa monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hallym Translational Research Institute, College of Medicine, Hallym University, Anyang-si 14068, Gyeonggi-do, Republic of Korea.
- Department of Internal Medicine, Hallym University Medical Center, College of Medicine, Hallym University, Anyang-si 14068, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Sung-Hwa Sohn, Bumjun Kim
Förderung
- the Korea Health Technology R&D Project
- the Patient-Centered Clinical Research Coordinating Center
- Hallym University Research Fund
- Korea Health Technology R&D Project
- Patient-Centered Clinical Research Coordinating Center
Zitieren
APA
Sohn, S. H., Sul, H., Kim, B., & Zang, D. (2025). Effects of Darbepoetin Alfa and Ferric Derisomaltose Plus Darbepoetin Alfa in Functional Iron-Deficiency Anemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052203
Vancouver
Sohn SH, Sul H, Kim B, Zang D. Effects of Darbepoetin Alfa and Ferric Derisomaltose Plus Darbepoetin Alfa in Functional Iron-Deficiency Anemia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052203
BibTeX
@article{Sohn2025,
author = {Sohn, Sung-Hwa and Sul, Heejung and Kim, Bumjun and Zang, Daeyoung},
title = {Effects of Darbepoetin Alfa and Ferric Derisomaltose Plus Darbepoetin Alfa in Functional Iron-Deficiency Anemia},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26052203}
}
EUVIMED